PubMed Daily Triage Digest — 2026-08-12

Run ID: 2026-08-12-attempt1-20260812T090000Z
Window: 2026-08-11T09:00Z → 2026-08-12T09:00Z (CRDT filter)
Topics scanned: 10 | Candidates reviewed: 116 unique PMIDs | Articles included: 22
HIGH priority: 9 | STANDARD: 13 | LOW: 0

🔴 HIGH PRIORITY

1. [Score 9] Personalized ctDNA profiling achieves universal AML MRD detection with HR 36 in transplant setting

PMID: 42579817 | Journal: Blood Cancer Discovery | Date: 2026-08-11
Topics: hematologic_malignancies · early_cancer_detection
Flags: mrd_liquid_biopsy · clinical_translation | Access: subscription

AML-CAPP-Seq, a whole-exome-informed personalized ctDNA assay, was evaluated in 56 AML patients with longitudinal plasma, blood, and bone marrow samples. Plasma ctDNA outperformed cellular MRD for relapse prediction (HR 17.8 for relapse-free survival; p<0.0001), and peri-transplant ctDNA dynamics stratified relapse risk with HR 36.0 (p=0.0009) in 29 allograft recipients. The assay tracked a median of 30.5 variants per patient and was applicable universally across AML subtypes.

Why it matters: Outperforms all standard-of-care MRD methods by a wide margin; the HR 36 in the transplant context is exceptional and directly actionable for clinical MRD surveillance strategy. Stanford group, Blood Cancer Discovery.

2. [Score 9] Deep learning achieves 97.5% accuracy for B-cell neoplasm detection from flow cytometry (n=3,070)

PMID: 42580478 | Journal: Modern Pathology | Date: 2026-08-11
Topics: hematologic_malignancies · ai_diagnostics
Flags: ai_platform · clinical_translation | Access: subscription

A three-stage deep learning system evaluated on 3,070 MSK clinical specimens achieved 97.5% case-level accuracy (95.6% sensitivity; 98.9% specificity) for mature B-cell neoplasm detection from flow cytometry across peripheral blood, bone marrow, and tissue samples. Lymphoma subtype prediction reached AUROC 0.925. The system generates interpretable embeddings for pathologist verification.

Why it matters: Large clinical dataset, interpretable outputs, MSK provenance, and near-pathologist accuracy across specimen types—highest deployment-readiness of any AI diagnostic article this cycle.

3. [Score 8] KMT2A-PTD identifies MDS subgroup with ~50% 3-year leukemia transformation; allo-HSCT is protective

PMID: 42580927 | Journal: Clinical Lymphoma, Myeloma & Leukemia | Date: 2026-07-15
Topics: hematologic_malignancies
Flags: genomic_medicine | Access: subscription

Multi-cohort study (137 PKUPH + 2,493 IWG-PM) establishes KMT2A-PTD as an independent predictor of leukemia transformation in MDS (3-yr rate 50% vs 19% without; p<.001). Allo-HSCT reduced cumulative transformation risk dramatically (relapse 17.6% vs 100% in the landmark analysis). No co-occurring mutation significantly modulated this risk.

Why it matters: Validates a genomic marker for an actionable clinical decision (early transplant referral) across two independent cohorts. Directly changes patient stratification in MDS.

4. [Score 8] Glofitamab achieves ORR 88–100% in R/R CNS lymphoma across 84 patients

PMID: 42579821 | Journal: Blood Cancer Discovery | Date: 2026-08-11
Topics: hematologic_malignancies · novel_therapeutics
Flags: high_unmet_need · clinical_translation | Access: subscription

Multicenter retrospective study (25 centers, 84 R/R CNSL patients) reports ORR 88–100% and CRR 59–81% with glofitamab-based therapy in PCNSL and SCNSL. Median PFS was 19.5 months (PCNSL) and 13.5 months (SCNSL). All CRS events were grade 1–2; ICANS 8%.

Why it matters: Response rates dramatically exceeding any historical benchmark in an essentially untreatable population. Largest multicenter dataset for glofitamab in CNS lymphoma to date. Retrospective design but compelling effect size.

5. [Score 8] KDM4C inhibition converts TP53-mutant AML to NK-cell-sensitive via cGAS-STING senescence pathway

PMID: 42579361 | Journal: Aging and Disease | Date: 2026-08-09
Topics: hematologic_malignancies
Flags: novel_mechanism · high_unmet_need | Access: open_access

In TP53-mutated AML cells (resistant to apoptosis by conventional agents), KDM4C inhibition with QC6352 induced cellular senescence and activated the cGAS-STING innate immune pathway, upregulating NK-activating ligands. Combination with NK cell therapy reduced leukemic burden and prolonged survival in mouse models.

Why it matters: Mechanistically novel approach to the most chemotherapy-refractory AML subtype; senescence-driven NK vulnerability is a credible new immunotherapy entry point for TP53-mutant AML.

6. [Score 8] Phase I oral PD-L1 inhibitors: two compounds advance after one discontinued for neuropathy

PMID: 42580817 | Journal: J Immunotherapy of Cancer | Date: 2026-08-11
Topics: novel_therapeutics
Flags: first_in_class · clinical_translation | Access: open_access (CC BY)

Phase I trials of three oral small-molecule PD-L1 inhibitors (INCB086550, INCB099280, INCB099318) in 424 advanced solid tumor patients demonstrated dose-dependent PK, confirmed PD-L1 target engagement, T-cell activation, and ORR ~9–11%. INCB086550 was discontinued due to immune-mediated peripheral neuropathy; INCB099280 and INCB099318 showed acceptable safety profiles.

Why it matters: Oral checkpoint inhibition would transform access and convenience for immunotherapy; first comprehensive Phase I data for three agents. Class-defining safety differentiation between compounds makes this actionable for development strategy.

7. [Score 7 + novel_mechanism flag] Plant auxin hormone as orthogonal ON-switch for CAR-T: in vivo B-cell lymphoma efficacy

PMID: 42579307 | Journal: Advanced Science | Date: 2026-08-11
Topics: novel_therapeutics · hematologic_malignancies
Flags: novel_mechanism | Access: open_access

Plant auxin receptor components (AFB1/IAA7) were repurposed as a non-immunogenic, dose-dependent, reversible CAR-T activation switch, demonstrated to achieve potent cytotoxicity against B-cell lymphoma in vitro and in vivo. AuxCAR-T cells maintained memory phenotype and showed reduced exhaustion versus conventional CAR designs.

Why it matters: True conceptual advance: orthogonal plant hormone signaling avoids immunogenicity of synthetic switches. Demonstrated in vivo efficacy. Pre-IND but mechanistically robust.

8. [Score 7 + high_unmet_need flag] First gene therapy for PFIC2 (VTX-802/AAV-BSEP): proof-of-concept in disease mouse model

PMID: 42579774 | Journal: Hepatology Communications | Date: 2026-08-11
Topics: rare_diseases
Flags: high_unmet_need · novel_mechanism | Access: open_access

VTX-802, an AAV gene therapy encoding ABCB11 (BSEP) under a constitutive liver promoter developed by Vivet Therapeutics, demonstrated dose-dependent normalization of serum transaminases and partial restoration of bile acid secretion in PFIC2 mice over 5 months—the first reported gene therapy approach for this rare transplant-dependent cholestasis.

Why it matters: First-of-class gene therapy for PFIC2; backed by an IND-stage company with NL/Spanish academic partnership; disease currently requires liver transplantation as definitive treatment. Strong unmet need, clear clinical translational path.

9. [Score 7 + novel_mechanism flag] PMS1-dependent non-canonical MMR repairs methylated CpG deamination — novel aging-mutation guardian

PMID: 42578366 | Journal: Nucleic Acids Research | Date: 2026-08-10
Topics: aging_longevity · precision_oncology
Flags: novel_mechanism · genomic_medicine | Access: open_access

Using APOBEC1-dCas9 targeted 5mC deamination, Institut Curie researchers showed that human PMS1 physically interacts with MBD4 and is required for non-canonical MMR (MutLβ/MutSα) of methylated CpG sites. PMS1 deficiency phenocopies MBD4-loss CpG>TpG hypermutation and contributes to the predominant aging-associated mutation signature in cancer.

Why it matters: New function for PMS1 as a methylated-genome guardian; directly links non-canonical MMR to the most frequent aging-associated mutational signature (CpG>TpG). Published in Nucleic Acids Research with rigorous experimental design.

🟡 STANDARD PRIORITY

10. [Score 7] Semaglutide vs bariatric surgery: MBS lowers composite CV risk by ~60% vs GLP-1 RA (n=18,793 matched)

PMID: 42580629 | Journal: Endocrine Practice | Date: 2026-08-11
Topics: cardiovascular_metabolic | Access: subscription

TriNetX propensity-matched cohort study (n=18,793 across T2DM and non-T2DM strata) found metabolic/bariatric surgery associated with ~60% lower composite cardiovascular risk than semaglutide at 5-year follow-up, with heart failure showing the greatest relative benefit (HR 0.29–0.35 favoring surgery).

11. [Score 6] Unsupervised clustering of 241,591 CBC/RUO/CPD specimens identifies thrombocytopenia-enriched phenotypes

PMID: 42578661 | Journal: Int J Laboratory Hematology | Date: 2026-08-11
Topics: cbc_diagnostics_ml | Access: subscription

k-means on 241,591 Sysmex analyzer specimens (41 features, PCA-reduced) identified 4 clusters; one cluster progressively captured 46→60→71% of specimens with platelet counts <150→<100→<50 ×10⁹/L. Limited mechanistic concordance (adjusted Rand index 0.14) but supports hypothesis-generating use of RUO analyzer parameters.

12. [Score 6] Open-source ML pipeline predicts blood culture positivity from CBC/DIFF/CPD; portable for LIMS deployment

PMID: 42578188 | Journal: Access Microbiology | Date: 2026-08-10
Topics: cbc_diagnostics_ml | Access: open_access (PMC)

Open-source, JSON-configurable Python pipeline (4 classifier types, nested CV, Boruta/RFE feature selection) trained on Sysmex XN CBC/DIFF/CPD for blood culture outcome prediction; models export directly for LIMS deployment without Python runtime. Addresses bloodstream infection test stewardship from routine parameters.

13. [Score 6] XGBoost ML autoverification outperforms rule-based CBC triage in 63,201 samples

PMID: 42576782 | Journal: J Clinical Laboratory Analysis | Date: 2026-08-11
Topics: cbc_diagnostics_ml | Access: subscription

XGBoost and other ML models outperformed rule-based autoverification for CBC testing at a Thai tertiary hospital (63,201 Sysmex XN-10 samples). XGBoost achieved 95–98% sensitivity with 68–81% specificity at tested recall thresholds; WBC abnormalities and platelet clumps drove non-verifiable classifications.

14. [Score 6] Semaglutide 2.4 mg improves EQ-5D utility in MASH F2/F3 at 72 weeks: ESSENCE health economics analysis

PMID: 42580587 | Journal: JHEP Reports | Date: 2026-08-11
Topics: cardiovascular_metabolic | Access: subscription

First utility data from ESSENCE Phase 3 trial (n=800): semaglutide 2.4 mg achieved statistically significant EQ-5D utility improvement versus placebo (Δ0.03; 95% CI 0.01–0.06; p=0.0015) at 72 weeks in MASH F2/F3. Data mapped from SF-36 using Rowen algorithm (UK tariff). Novo Nordisk-sponsored.

15. [Score 6] Logic-gated CARs: unified Boolean framework for programmable cell-based immunotherapy

PMID: 42580938 | Journal: Trends in Biotechnology | Date: 2026-08-11
Topics: novel_therapeutics | Access: subscription

Comprehensive review proposing unified Boolean logic framework (YES/OR/AND/INHIBIT/sequential/hybrid) for classifying logic-gated CAR architectures; compares systems by molecular mechanism, reversibility, modularity, and clinical translatability. Practical reference for CAR design and clinical trial landscape.

16. [Score 6] Anti-CD47 LD002 achieves potent tumor clearance without hemagglutination; NHP MTD 744 mg/kg

PMID: 42580138 | Journal: Int Immunopharmacology | Date: 2026-08-11
Topics: novel_therapeutics · hematologic_malignancies | Access: subscription

LD002 (silenced-Fc anti-CD47 mAb) achieved 79% TGI (lymphoma) and 100% tumor clearance (SCLC) at 3 mg/kg in xenografts without dose-dependent hemagglutination; NHP single-dose MTD 744 mg/kg with no clinically meaningful hematologic findings. Addresses primary translational bottleneck for CD47-SIRPα checkpoint class.

17. [Score 6] GLP-1 RAs fail in symptomatic AD (EVOKE); review argues for pre-symptomatic metabolic intervention

PMID: 42580680 | Journal: J Neuroendocrinology | Date: 2026-08
Topics: cardiovascular_metabolic | Access: subscription

Critical review of EVOKE/EVOKE+ trials concluding GLP-1 RAs do not slow clinical AD progression in symptomatic patients, despite positive biomarker effects. Review argues pre-symptomatic, metabolically enriched populations may still benefit; refocuses the AD GLP-1 RA hypothesis.

18. [Score 6] A×G×E×D framework proposes bioengineered cardiac microtissues for modeling cardiac aging

PMID: 42579795 | Journal: JCI Insight | Date: 2026-08-10
Topics: aging_longevity | Access: open_access

Perspective from University of Pittsburgh proposes Age × Genetics × Environment × Drug A×G×E×D framework integrating cardiac microtissues and nanotechnology for multidimensional cardiac aging research. Addresses the gap that most preclinical cardiac studies omit age as a primary variable.

19. [Score 5] Metformin at the convergence of aging and longevity: AMPK/mTOR/epigenetic mechanisms reviewed

PMID: 42579881 | Journal: Aging (Albany NY) | Date: 2026-08-10
Topics: aging_longevity | Access: open_access

Narrative review positioning metformin as a geroprotective agent acting through convergent aging pathways (AMPK, mTOR, mitochondria, epigenetics); contextualizes observational longevity evidence and highlights TAME trial as the key validation study.

20. [Score 5] AI review for lumbar radiography: deployment strategies in low-resource clinical settings

PMID: 42580813 | Journal: BMJ Health & Care Informatics | Date: 2026-08-11
Topics: ai_diagnostics · sentinel | Access: open_access

Review of DL applications for lumbar radiograph interpretation covering disc degeneration, vertebral fractures, and alignment; emphasizes practical AI deployment in resource-constrained environments without specialized infrastructure.

21. [Score 5] XLH bone architecture deficits persist on conventional treatment by HR-pQCT (n=16)

PMID: 42579009 | Journal: J Bone and Mineral Metabolism | Date: 2026-08-11
Topics: rare_diseases | Access: open_access

Case-control (16 XLH patients vs matched controls): HR-pQCT revealed peripheral trabecular bone deficits not captured by axial DXA in patients receiving calcitriol and phosphate supplementation; 33% radius DXA recommended as complementary monitoring site.

22. [Score 5] GLP-1 RAs in HFpEF vs HFrEF: symptom and QoL benefit is EF-specific (review)

PMID: 42580921 | Journal: J Cardiothoracic Vascular Anesthesia | Date: 2026-07-19
Topics: cardiovascular_metabolic | Access: subscription

Continuing pharmacotherapy series review establishing HFpEF-specific benefit of GLP-1 RAs for symptom burden and exercise tolerance; neutral/uncertain effects in HFrEF. Covers sympathetic inhibition, mitochondrial, and anti-inflammatory protective mechanisms.

Coverage Summary

*Cross-listed articles counted under their primary topic assignment.

Generated by Friday (OpenClaw) · 2026-08-12T09:00Z · Attempt 1 of 3